Non CF-bronchiectasis: Aetiologic, clinical, radiological, microbiological and functional profile in a Greek population
Christina Triantafyllidou (Athens, Greece), Christina Triantafillidou, Michail Toumbis, Petros Bakakos, Kyriaki Tsikritsaki, Adamantia Liapikou, Katerina Malagari, Katerina Dimakou
|   |
Hacettepe University experience: Clinical evaluation of 218 primary ciliary dyskinesia patients
Nagehan Emiralioglu (Ankara, Turkey), Nagehan Emiralioglu, Ugur Özçelik, Ebru Yalçin, Deniz Dogru Ersöz, Nural Kiper
| |
Atorvastatin as an anti inflammatory in bronchiectasis
Pallavi Bedi (Edinburgh, United Kingdom), Pallavi Bedi, James Chalmers, Adriano Rossi, Adam Hill
| |
Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA)
Rocio Jimeno Galvan (Algeciras, Spain), Rocío Jimeno, Belén Navas, Jose Manuel Vaquero, Francisco Casas, Alicia Padilla, Enrique Gonzzlez-Moya, Manuel Arenas, Juan Carlos Bioque, Jose Luis López-Campos, Soledad Cano, Silvia Merlos, Agustin Valido
| |
Audit investigating self-management of bronchiectasis at University Hospital Llandough, Wales
Sabena Ali (Bristol, United Kingdom), Sabena Ali, Jamie Duckers, Dawn Lau
| |
A single isolation of pseudomonas aeruginosa predicts poor quality of life and increased exacerbation frequency in adult bronchiectasis
james hill (Dundee, United Kingdom), James Hill, Duncan Renton, Hani Abo-Leyah, Megan Crichton, Simon Finch, Thomas Fardon, James Chalmers
| |
The impact of acute air pollution fluctuations on non-cystic fibrosis bronchiectasis pulmonary exacerbations: A case-crossover analysis
Pieter Goeminne (Bornem, Belgium), Pieter Goeminne, Pallavi Bedi, Michal Kicinski, Lauren Richardson, Kees De Hoogh, Ben Nemery, Tim Nawrot, Michael Loebinger, Adam Hill, Lieven Dupont
| |
DLCO predicts disease severity and mortality in patients with non-cystic fibrosis bronchiectasis
Melissa McDonnell (Galway, Ireland), Melissa McDonnell, Michael O’Mahony, David Breen, J.J. Gilmartin, Anthony O’Regan, Robert Rutherford
| |
Increased disease severity and mortality associated with the Bronchiectasis-GORD phenotype
Melissa McDonnell (Galway, Ireland), Melissa McDonnell, O’Mahony Michael, Breen David, O’Regan Anthony, Rutherford Robert
| |
Exacerbations and pneumonia in bronchiectasis: Clinical and microbiological characterization
Victoria Alcaraz Serrano (Barcelona, Spain), Victoria Alcaraz, Eva Polverino, Edmundo Rosales, Rosa Maria Giron, Rosario Mendendez, Montserrat Vendrell, Antoni Torres
| |
Nontuberculous mycobacteria in the Danish population, incidence rate and clinical importance during 24 years
Thomas Stig Hermansen (Rødovre, Denmark), Thomas Hermansen, Troels Lillebaek, Erik Svensson, Pernille Ravn
| |
Patterns of isolation and drug sensitivity in non-tuberculous mycobacteria
Steven Cowman (London, United Kingdom), Steven Cowman, Burns Katie, Benson Susan, Wilson Robert, Loebinger Michael
| |
The value of rapid speciation of nontuberculous mycobacteria (NTM) by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF)
Neeraj Shah (New Malden, United Kingdom), Neeraj Shah, Rebecca Gorton, Jennifer Canizales, Gina Birch, Timothy McHugh, Marc Lipman
| |
Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI)
Kenneth N. Olivier (Bethesda, United States of America), Kenneth N. Olivier, Gina Eagle, John P. McGinnis II, Liza Micioni, Barbara A. Brown-Elliott, Richard J. Wallace, Jr.
| |
Feasibility study for a randomized controlled trial of pseudomonas aeruginosa eradication treatment in patients with bronchiectasis
Hani Abo-Leyah (Dundee, United Kingdom), Hani Abo-Leyah, Marilyn Clark, James Hill, Thomas Fardon, James Chalmers
| |
Patients in randomized clinical trials of bronchiectasis are only partially representative of clinical practice: A European cohort study
James D. Chalmers (Perth, United Kingdom), James Chalmers, Melissa McDonnell, Pieter Goeminne, John Davidson, Robert Rutherford, Megan Crichton, Thomas Fardon, Adam Hill, Lieven Dupont, Stefano Aliberti, Anthony De-Soyza
| |
Heterogeneity in bronchiectasis service provision in Europe: Baseline data from the European bronchiectasis registry (EMBARC)
James D. Chalmers (Perth, United Kingdom), James Chalmers, Eva Polverino, Anthony De Soyza, Felix Ringshausen, Marlene Murris, Wim Boersma, Antoni Torres, Montserrat Vendrell, J. Stuart Elborn, Francesco Blasi, Stefano Aliberti, On Behalf of the EMBARC Clinical Research Collaboration
| |